Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Highly active antiretroviral therapy (HAART) has had a significant impact on the natural history of human immunodeficiency virus (HIV) infection, leading to a remarkable decrease in its morbidity and mortality, but is frequently associated with clinical and metabolic complications. Fat redistribution or lipodystrophy, hypertriglyceridaemia, hypercholesterolaemia, insulin resistance and diabetes mellitus have been extensively reported in subjects treated with protease inhibitor (PI)-based antiretroviral regimens. In particular, dyslipidaemia occurs in up to 70-80% of HIV-infected individuals receiving HAART and can be associated with all the available PIs, although hypertriglyceridaemia appears to be more frequent in patients treated with ritonavir, ritonavir-saquinavir, or ritonavir-lopinavir. The potential long-term consequences of HAART-associated hyperlipidaemia are not completely understood, but an increased risk of premature coronary artery disease has been reported in young HIV-positive persons receiving PIs. Dietary changes, regular aerobic exercise and switching to a PI-sparing regimen may act favourably on dyslipidaemia. Lipid-lowering therapy is often required with statins or fibrates. The choice of hypolipidaemic drugs should take into account potential pharmacological interactions with antiretroviral agents.

[1]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[2]  L. M. Lehman,et al.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.

[3]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[4]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[5]  R. Hameed,et al.  Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. , 2000, Clinical therapeutics.

[6]  B. Gazzard.  What are the perceived advantages and disadvantages of non‐nucleoside reverse transcriptase inhibitors as first‐line therapy? , 2000, HIV medicine.

[7]  S. Hammer,et al.  Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. , 2000, Archives of internal medicine.

[8]  ntonio,et al.  A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE , 2000 .

[9]  Gazzard Bg.  What are the perceived advantages and disadvantages of non-nucleoside reverse transcriptase inhibitors as first-line therapy? , 2000 .

[10]  W. K. Henry,et al.  Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Penzak,et al.  Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. , 2000, Scandinavian journal of infectious diseases.

[12]  Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. , 2000, AIDS.

[13]  S. Staszewski,et al.  Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. , 2000, European journal of medical research.

[14]  M. Schambelan,et al.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. , 2000 .

[15]  K. Sepkowitz,et al.  Coronary artery disease and human immunodeficiency virus infection. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[17]  R. Weber,et al.  Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. , 2000, AIDS.

[18]  J. Ruidavets,et al.  An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients , 2001, AIDS.

[19]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[20]  L. Calza,et al.  Use of Fibrates in the Management of Hyperlipidemia in HIV-Infected Patients Receiving HAART , 2002, Infection.

[21]  P. Sax,et al.  Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. , 2002, The Journal of infectious diseases.

[22]  Richard D. White,et al.  Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. , 2002, Atherosclerosis.

[23]  P. Morlat,et al.  Efavirenz-associated severe hyperlipidemia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Ragnaud,et al.  Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  R. Paredes,et al.  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Serrano-Ríos,et al.  Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Katherine C. Wu,et al.  Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. , 2002, American heart journal.

[28]  A. Simon,et al.  Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era , 2003, AIDS.

[29]  D. Hui.  Effects of HIV protease inhibitor therapy on lipid metabolism. , 2003, Progress in lipid research.

[30]  L. Calza,et al.  Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. , 2003, International journal of antimicrobial agents.

[31]  S. Mauss,et al.  Differentiating hyperlipidaemia associated with antiretroviral therapy , 2003, AIDS.

[32]  T. Louis,et al.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[33]  F. Gutiérrez,et al.  Lopinavir Plasma Concentrations and Changes in Lipid Levels During Salvage Therapy with Lopinavir/Ritonavir‐Containing Regimens , 2003, Journal of acquired immune deficiency syndromes.

[34]  M. Dubé,et al.  Lipid abnormalities. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Leonardo Calza,et al.  Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART , 2003, AIDS.